HTA Glossary

Willingness-to-pay threshold (WTP)

Also known as: Cost-effectiveness threshold

A willingness-to-pay threshold, also called a cost-effectiveness threshold, is the maximum amount a decision-maker is prepared to pay for one extra unit of health benefit, usually one quality-adjusted life year (QALY). A technology whose ICER falls below the threshold is generally regarded as cost-effective.

By HTA Course · Last reviewed

In more detail

WTP explained

Published values differ widely. From April 2026 NICE in England uses a standard range of £25,000 to £35,000 per QALY gained for technology appraisals, up from £20,000 to £30,000. In the United States the Institute for Clinical and Economic Review bases its price benchmarks on $100,000 to $150,000 per QALY. Many countries state no explicit threshold.

There are two ways to read a threshold. On the demand side it expresses what society is willing to pay for health. On the supply side it expresses opportunity cost: the health given up elsewhere when a fixed budget is spent on the new technology.

A threshold is rarely applied mechanically. Committees also weigh the severity of the disease, the uncertainty in the evidence and other factors. In formulas the threshold is often written as λ (lambda).

Go further

Learn HTA from A to Z

The HTA Course puts this term in context, with worked examples and interactive lessons across 15 modules and 79 self-paced lessons, and a certificate of completion.